Dubbelt upp för Korbinian Löbmann

I år blir femte gången Korbinian Löbmann modererar mötet New Updates in Drug Formulation & Bioavailability i Köpenhamn. För första gången tar han sig nu även an kongressen The Future of Swedish & Danish Life Science i Lund.

The Swedish Life Science Office: “We lost in both coordination and manpower”

Since the turn of the year, the Swedish government’s life science office has operated at a lower capacity. Life Science Sweden has spoken to Pontus Holm, Departmental Secretary at the office, about the ongoing work.

AstraZeneca moves to brewery quarters in central Copenhagen

AstraZeneca in Denmark is moving its business into central Copenhagen and the old brewery quarters in Carlsberg Byen.

Nanexa develops depot formulation of the diabetes and obesity drug Saxenda

Uppsala-based company Nanexa has signed an agreement with a German contract research company to start a clinical study with a monthly depot of liraglutide. The drug is currently approved for the treatment of diabetes and obesity.

This is the future location of the new national innovation cluster

Mölndal and Goco Health Innovation City will be the site of a new national innovation cluster for advanced therapies. The business community and the Swedish government are splitting the costs of the project, which is expected to produce new treatments

Looking for greater Nordic cooperation – “We have Norway and Finland in our sights”

How can Medicon Valley Alliance bring the big pharmaceutical companies back to the organisation? Life Science Sweden discussed this topic and others with the cluster organisation’s new radar pair.

New diagnostic rules raise concerns

In a panel discussion, several voices from academia and the industry expressed concerns about the transition to the new regulatory framework for in-vitro diagnostics (IVDR). They argue that it may create significant differences between regions, and patients may be affected.

Conference on Alzheimer’s reveals several advances in the field

In Gothenburg, Sweden, researchers and pharmaceutical companies from all over the world gathered to discuss one specific issue – neurological diseases. Life Science Sweden has talked to some of those that attended the conference.

“I am driven by the desire to develop a product that can be sold worldwide”

Ranked number one in the world by the WHO in diarrhoea research and soon in phase III studies for its vaccine candidate – Scandinavian Biopharma is rushing forward in the pursuit of the world’s first ETEC vaccine. Meet the company’s CEO Björn Sjöstrand.

”AI som både imponerar och skrämmer”

"Tidigare har jag sällan varit särskilt imponerad över något som varit AI-producerat. Men det här är något helt annat", skriver Samuel Lagercrantz i en ledare om Chat GPT och om AI i sjukvården.

Editorial: ”AI that both impresses and frightens”

”In the past, I've rarely been particularly impressed by something that was produced by AI. But this is something completely different”, Samuel Lagercrantz writes in an editorial.

Rapid development in blood analysis – “Sweden is leading the race”

Thousands of analytical tests using just one single drop of blood. What was revealed as a hoax just a few years ago is now a reality, according to KTH professor and serial entrepreneur Mathias Uhlén.

Precision medicine centre: “Extensive activity on several fronts”

Two years ago, the Karolinska Institutet and the Karolinska University Hospital announced that they would jointly launch the Precision Medicine Centre. Medtech Magazine called Anna Wedell, who is heading the work, to find out…

Höstens mest lästa krönikor

Här nedan läser du de mest lästa krönikorna i Life Science Sweden och systertidningen Medtech Magazine från hösten och vintern.

“Photon counting in computed tomography is the holy grail”

Erik Fredenberg, a researcher in physics at KTH and GE, is working to implement photon-counting CT in clinics. To shorten lead times and reduce the radiation dose in patients, he is setting out to develop a framework for virtual clinical trials for the technology.

She creates pharmaceuticals on a 3D printer

The correct dosage for each individual, regardless of whether the pharmaceutical is for a seriously ill child or a frail elderly person, is the mission of a well-advanced project with 3D-printed drugs at Uppsala University. “It will soon be available

Outsourcing som strategi för ökad trovärdighet

Idag, torsdag, pågår Life Science Swedens event Pharma Outsourcing på Stockholm Waterfront. Under en av föreläsningarna jämfördes för- och nackdelar med att ta sig an uppgifter och problem internt med att köpa in tjänster.

Dags för ”ett av våra mest efterfrågade möten”

The stomach medication that became the biggest blockbuster of the 1990s

The omeprazole molecule was synthesised as early as 1979, but it took many years before the then Astra had an approved pharmaceutical. Once this happened, a tablet was available that was soon to help millions of people worldwide and break all sales records.

Magmedicinen som blev 90-talets största blockbuster

Redan 1979 syntetiserades omeprazolmolekylen. Men det kom att dröja många år innan dåvarande Astra hade ett godkänt läkemedel. När det väl skedde fanns en tablett som kom att hjälpa miljontals människor i världen – och slå alla försäljningsrekord.

Här är hela listan – De viktigaste svenska medicininnovationerna

Högst upp på Life Science Swedens rankning över moderna svenska innovationer inom medicinområdet finns Losec från dåvarande Astra.

He is zooming in on topical preparations

According to Zelmic CEO David Sagna, topical products in drug development is a growing market, and to keep pace with the development, the company is awaiting approval for its new GMP facility.

Swedish breakthrough in Alzheimer’s: “We can finally present great data”

Treatments for Alzheimer’s disease are currently among the hottest topics in drug development. Two Swedish research companies with high ambitions and successes in the field participated in Bioscience 2022 conference at Life City in Hagastaden, Stockholm.

”Ett perfekt möte på hösten”

"Som vanligt är jag mest sugen på det oväntade". Så svarar Johan Rockberg, professor vid KTH, på frågan om vad han ser mest fram emot på kongressen Bioscience som han ska moderera nästa vecka.